Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 10,863 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
Interventions: Placebo, quetiapine fumarate XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more

Conditions: Breast Cancer
Interventions: anastrozole, tamoxifen citrate, Radiation Therapy; Drug · Radiation
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Female only
Enrollment: 3,104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 724
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Olomorasib, Pembrolizumab, Durvalumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 93
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 72 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 86
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more

Conditions: Asthma
Interventions: AZD4604, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more

Conditions: Chronic Low-back Pain
Interventions: Enhanced Self-Care (ESC), Acceptance and Commitment Therapy (ACT), Evidence-Based Exercise and Manual Therapy (EBEM), Duloxetine; Behavioral · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Redwood City, California • San Diego, California • San Francisco, California + 9 more

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Bradycardia
Interventions: St. Jude Medical Tendril MRI™ lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 66
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 62 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Itacitinib, Placebo, Prednisone, Methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 49
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 38 more

Conditions: Influenza
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 28 more

Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions: Tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Icosabutate, Placebo; Drug
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 38
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more

Conditions: Cancer Survivor
Interventions: Cognitive Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 25 Years to 34 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 326
States / cities: Fairbanks, Alaska • Fort Smith, Arkansas • Anaheim, California + 221 more

Conditions: Plasma Cell Myeloma
Interventions: isatuximab SAR650984, lenalidomide, dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more

Conditions: Neuroblastoma
Interventions: DFMO; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 21 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 19 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 229
States / cities: Athens, Alabama • Cullman, Alabama • Fairhope, Alabama + 189 more

Conditions: Epilepsy, Adherence, Medication
Interventions: Automated Digital Reminders, Individualized Adherence Feedback Report, Individual Adherence Feedback Report with Social Norms; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more

Conditions: Rotator Cuff Tear
Interventions: Bioinductive implant; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Orange, California • Glenwood Springs, Colorado • Gulf Breeze, Florida + 15 more

Conditions: Joint Diseases
Interventions: 28 mm ceramic head on ceramic acetabular liner., 28 mm ceramic head on polyethylene liner; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 2
States / cities: Denver, Colorado • Columbus, Ohio

Conditions: Lung Cancer, NSCLC, Brain Metastases
Interventions: Alectinib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Joshua Palmer; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Columbus, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more

Search by objective public record fields.

Generalized Anxiety Disorder Adjunct Study

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

The BEST Trial: Biomarkers for Evaluating Spine Treatments

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

SJM Brady MRI Post Approval Study

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

A Phase 2b Study of Icosabutate in Fatty Liver Disease

Work Ability in Young Adult Cancer Survivors

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Behavioral Economics and Adherence in Teens (BEAT!)

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Rotation Medical Bioinductive Implant Database Registry

28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)